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In vertebrates and, specifically, in mammals, energy homeostasis is achieved by the
integration of metabolic and neuroendocrine signals linked to one another in an
intricate network hierarchically responding to the tight modulating action of hormones
among which thyroid hormones (THs) play a central role. At the cellular level,
3,5,3′-triiodo-L-thyronine (T3) acts mainly by binding to specific nuclear receptors (TRs)
but actually it is becoming more and more evident that some T3- actions are independent
of TRs and that other iodothyronines, such as 3,5-diiodo-L-thyronine (T2), affect energy
metabolism and adiposity. In the postgenomic era, clinical and basic biological researches
are increasingly benefiting from the recently developed new omics approaches including,
among the others, proteomics. Considering the recognized value of proteins as excellent
targets in physiology, the functional and simultaneous analysis of the expression level
and the cellular localization of multiple proteins can actually be considered fundamental
in the understanding of complex mechanisms such as those involved in thyroid control
of metabolism. Here, we will discuss new leads (i.e., target proteins and metabolic
pathways) emerging in applying proteomics to the actions of T3 and T2 in conditions of
altered energy metabolism in animal tissues having a central role in the control of energy
balance.
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INTRODUCTION
Strong evidence supports an essential role for thyroid hormones
[THs, 3,5,3′,5′-tetraiodo-L-thyronine (T4), and 3,5,3′-triiodo-L-
thyronine (T3)] in the physiological regulation of whole-body
energy balance and metabolism in homoeothermic species and,
specifically, in mammals. Moreover, THs control a bulk of phys-
iological processes such as growth, development, and metabolic
rate (for a recent review on thyroid hormone signaling in energy
metabolism, see Brent, 2012; Davis et al., 2013; López et al., 2013;
McAninch and Bianco, 2014; Mullur et al., 2014). However, the
network of events involved in the actions of THs is complicated
and still incompletely understood. Integrative omic approaches,
such as transcriptomics and proteomics, hold great promise
and actually are having increasing applications in the study of
complex biological systems. As far as it concerns the metabolic
actions of THs, a large amount of data is available from tran-
scriptomic studies which have been quite extensively performed
to identify T3-target genes in several models (for review see,
Silvestri et al., 2011a, and references therein) actually providing
a cornucopia of novel information on the regulation of tran-
scription by THs (e.g., the potential of T3 to regulate miRs,
Visser et al., 2009). However, the intrinsic nature of these stud-
ies provided no information concerning the status of the cor-
responding encoded proteins, which, indeed, enable to assess
the programs actually executed. On the other hand, proteomic
approaches [such as, among the others, two-dimensional gel
electrophoresis (2-DE) and mass spectrometry (MS)], allow the
simultaneous measurement and comparison of the expression
levels of hundreds of proteins as well as the identification of
other aspects of protein functions (i.e., post-translation modifi-
cations), giving rise to a fuller understanding of cellular functions
(for recent review, see Johnson and White, 2012; Feeney and
Schöneich, 2013; Zhang et al., 2013). However, intrinsic lim-
itations inherent to the more classical approaches—including,
among the others, difficulties in the resolution of proteins with
extreme isoelectric point values, loss of very hydrophobic pro-
teins, absence of proteins of high and low molecular weights
and poor resolution of low-abundance proteins—cannot be
ignored (Sriharshan et al., 2014; and for review see, Wittig
and Schägger, 2009; Silvestri et al., 2011a,b). In this review,
we will outline the new leads emerging from the application
of proteomic analyses to the actions of thyroid hormones in
the regulation of energy balance in conditions of altered energy
metabolism.
PROTEOMIC ANALYSIS PERTAINING TO THE ACTIONS OF T3
Hypothyroidism and hyperthyroidism are two pathological con-
ditions in which energy metabolism is altered leading to hypo-
and hyper-metabolic states, respectively. Metabolically active
tissues, such as liver and skeletal muscle, retain the ability to
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respond, to counteract and to adapt to such alterations by
modifying gene/protein expression patterns.
The first application of proteomic tools to the modulations
that T3 exerts in vivo over tissue proteins can be traced back to
1981. Analyzing the liver of normal, thyroidectomized, and thy-
roidectomized plus T3 treated rats, by using classical 2-DE, it has
been shown that changes in the thyroid state significantly affect
the composition of the hepatic nucleoproteins (Nikodem et al.,
1981).
To obtain a more comprehensive identification and character-
ization of molecular events/pathways associated with altered thy-
roid states, more recently, a high-resolution differential proteomic
analysis, combining 2-DE and subsequent matrix-assisted laser
desorption/ionization time-of flight mass spectrometry (MALDI-
ToF MS), was performed, thus providing the first systematic
identification of T3-induced changes in the protein expression
profiles of liver and skeletal muscle of hypothyroid rats (Silvestri
et al., 2006, 2007).
In the liver, among the 600 detected spots, 53 proteins (8%
of the analyzed proteome) resulted to be significantly affected
by T3 treatment. On the base of their identity, the unambigu-
ously identified proteins were classified as involved in substrate
(e.g., aldehyde-dehydrogenase and α-enolase) and lipid (e.g.,
short chain-specific acyl-CoA dehydrogenase and 3-ketoacyl-
CoA thiolase) metabolism, energy metabolism (e.g., ATP syn-
thase α-chain), detoxification of cytotoxic products (e.g., catalase
and glutathione-S-transferase), calcium homeostasis (senescence
marker protein 30), amino acid catabolism (arginase-1), and the
urea cycle (ornithine carbamoyltransferase). Interestingly, 76%
of these proteins were down-regulated in hyperthyroid rats vs.
hypothyroid ones. These proteomic data gave new support to
the transcriptome analyses revealing the idea that negative reg-
ulation by T3 on gene expression might be much more preva-
lent than previously thought (Feng et al., 2000). Among the
down-regulated proteins, there were ornithine carbamoyltrans-
ferase, arginase 1, the peroxisomal catalase, and the cytoplas-
mic glutathione-S-transferase. This allowed to deeper understand
how the thyroid state, in the liver, modulates urea and ammonia
production (Marti et al., 1988) and promotes oxidative stress (for
recent review, see Videla, 2010).
On the other hand, among the few up-regulated proteins,
α-enolase resulted to be strongly induced (+240%) by T3 admin-
istration. This further supported the notion that T3 stimu-
lates gluconeogenesis and glucose production in the liver thus
opposing to the action of insulin (for recent review, see Brenta,
2011).
Concerning skeletal muscle, the whole-cell protein content
of gastrocnemius muscle was analyzed. With the detection lim-
its set, a proteome of about 200 spots was obtained. 33 pro-
tein spots (15% of the analyzed proteome) resulted to be
significantly affected by T3 treatment. When comparing hyper-
thyroid vs. hypothyroid rats, 70% of the unambiguously iden-
tified proteins (20 protein spots) were up-regulated. The largest
group of affected proteins was involved in substrate (e.g.,
pyruvate kinase muscle isozyme and malate dehydrogenase)
and energy metabolism (e.g., creatine kinase M-type and ATP
synthase beta chain), another important group was represented
by stress-induced proteins (HSPs), and the remainder were impli-
cated in structural features or gene expression (transcription,
translation) (e.g., chromodomain-helicase-DNAbinding protein
1 and eukaryotic translation initiation factor 3 subunit 10).
Importantly, the thyroid state resulted to induce simultaneous
changes in the expression levels of proteins involved in both
structural and metabolic features of the gastrocnemius muscle.
Specifically, hypothyroidism and hyperthyroidism were found
to induce a structural and metabolic shift toward a slower and
a faster phenotype, respectively (Silvestri et al., 2007). Indeed,
in accordance with a predominant expression of myosin heavy
chain (MHC) Ib over MHC IIb in hypothyroidism and a rever-
sal of this ratio after T3 administration, the expression level of
myosin regulatory light chain 2, typical of slow-twitch fibers,
was strongly increased in hypothyroidism, with hyperthyroidism
significantly reducing it. Coherently, and in accordance with a
generally increased metabolic dependence on glycolysis in hyper-
thyroidism, β-enolase, pyruvate kinase, and triosephosphate iso-
merase protein levels were significantly increased following T3
treatment.
All together, the so far described data allowed to obtain an at
glance evaluation of the effects elicited by T3 in hypothyroid rats,
highlighting the tissue-specific proteomic response: in the liver
T3 produces a general down regulation of affected proteins likely
modulating substrate metabolism (i.e., aminoacid catabolism); in
the gastrocnemius muscle T3 produces a more pronounced effect
of up-regulation likely promoting energy metabolism and glucose
utilization.
An even more recent study was published in which pro-
teomic approaches were used to obtain new information on the
in vivo actions of T3. Specifically, the early changes induced
in rat liver by a single mitogen dose of T3 were characterized
(Severino et al., 2011). Many enzymes, directly or indirectly
involved in energy metabolism and oxidative stress, were identi-
fied among the differentially expressed proteins furnishing new
insight into the mechanisms by which T3 induces hepatocyte
proliferation.
These studies, as a whole, allowed the identification of pro-
teins previously not known to be regulated by T3 and might
prompt the scientific community to go further with proteomic-
based approaches to increase the awareness of the multiple cell
processes and signaling pathways involved in the effects of such
iodothyronine.
PROTEOMIC ANALYSIS PERTAINING TO THE ACTIONS OF T2
Overweight and adiposity lead to impaired energy balance with
several other metabolic disturbances taking place. T3 exerts both
hypolipidemic and hyperlipidemic effects due to its control of
lipolytic and lipogenic pathways. Interestingly, accumulating evi-
dence has indicated that several metabolic effects of THs can be
attributed to endogenous metabolites of T3 that actually can be
considered new discovered arms by which the thyroid gland can
control whole body energy homeostasis (Goglia, 2005; Moreno
et al., 2008; Piehl et al., 2011; Senese et al., 2014). 3,5-diiodo-
l-thyronine (T2) is receiving particular attention in view of its
specific excito-metabolic actions (for recent review, see Coppola
et al., 2014; Senese et al., 2014 and references within).
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The effects andmechanisms underlining the actions of T2 have
so far been studied both in vivo and in vitro (Scapin et al., 2010;
Grasselli et al., 2011, 2012) models (for recent review, see Silvestri
et al., 2013; Vergani, 2014). Up to now, a controversy exists as far
as it concerns the nature of such mechanisms and the possibility
that T2 might exert some of its effects in a TR-dependent manner
(Mendoza et al., 2013; Jonas et al., 2014; Navarrete-Ramírez et al.,
2014; Orozco et al., 2014). However, it cannot be excluded that
the putative interaction of T2 with nuclear TRs, at least in mam-
malian species, might be a consequence of the high doses used
(Goldberg et al., 2012; Jonas et al., 2014).
Of the currently described in vivo effects of T2, a particu-
lar physiological and pharmacological relevance appears to be
associated with those that we can define as hypolipidemic and
anti-steatotic effects, that have been described in several animal
models of overweight and thus of altered energy metabolism
[high fat (HFD) or high cholesterol diet-fed rodents] (Lanni et al.,
2005; Grasselli et al., 2008; Mollica et al., 2009; de Lange et al.,
2011; Moreno et al., 2011; Goldberg et al., 2012; Jonas et al.,
2014) and in humans too (Antonelli et al., 2011). Importantly, a
more recent study has reported that T2 administration stimulates
energy expenditure and reduces body mass gain also in standard
diet fed aging rats (Padron et al., 2014).
As far as it concerns the anti-steatotic effect of T2 elicited
in the liver of HFD rats (at the pharmacological but not thy-
rotoxic dose of 25μg/100 g body weight), to further identify
candidate molecules as well as molecular/biochemical pathways
linking fat consumption, the pathogenesis of hepatic steatosis,
and mitochondrial functions, a high-resolution differential pro-
teomic analysis [by combining 2-DE, MALDI-ToF MS, Blue
Native-PAGE (BN-PAGE) and in silico analysis] was performed
(Silvestri et al., 2010).
Data analysis demonstrated that the steatotic effect of HFD,
and the anti-steatotic effect of T2-treatment are strictly asso-
ciated with altered expression levels of several proteins and
enzymes involved in key liver metabolic pathways. These
FIGURE 1 | Synoptic of the workflow of the proteomic approaches
so far utilized to obtain new information on the actions that T2
and T3 exert in vivo in key metabolically active tissues central
in the control of energy balance. The described studies were
performed as integrated approaches including 2D-E, mass
spectrometry, and bioinformatic tools (Silvestri et al., 2006, 2007,
2010; Moreno et al., 2011). Abbreviations: N, standard diet fed
control rats; HFD, high fat diet fed rats; HFD+T2, high fat diet fed
rats treated with T2; Eu, euthyroid rats; Hypo, hypothyroid rats;
Hypo+T3, hyperthyroid rats.
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pathways included: fatty acid metabolism [e.g., carnitine O-
palmitoyltransferase (CPT) 2 and long-chain fatty acid-CoA
ligase], ketone-bodies [e.g., hydroxymethylglutaryl-CoA (HMG-
CoA) synthase] and energy metabolism (e.g., ATP synthase sub-
unit alpha), amino acid and nitrogen metabolism (e.g., glutamate
dehydrogenase 1), the urea cycle (e.g., carbamoyl-phosphate syn-
thase), the stress response (e.g., HSP60 and catalase) and protein
turnover (e.g., proteasome component C2 and proteasome iota
chain). Importantly, after T2-treatment, the majority of these
proteins exhibited alterations in their expression level that were
opposite to those observed in HFD and normalized vs. those
observed in standard diet fed control rats (Silvestri et al., 2010).
For example, long-chain fatty acid-CoA ligase and ATP synthase
subunit alpha, both having a central role in lipid biosynthesis
and energy metabolism, were significantly up-regulated by HFD
(thus positively correlating with the steatotic condition present
in HFD rats) and normalized in their expression levels by T2
treatment, thus highlighting some of the biochemical bases of the
hypolipidemic effect of T2. The obtained proteomic data were
corroborated by the in silico analysis (i.e., pathway and network
analysis by using the Ingenuity® Systems, www.ingenuity.com).
Of note, the network concerning the effects of T2 contained two
external coupling namely HMG-CoA synthase and CPT, sup-
porting, once again, the centrality of lipid metabolism in the
action of T2 in the liver. Moreover, as mitochondria appeared
to be a major target for the metabolic and energy adaptations
induced by fat-overload, and displayed a significant response,
in terms of their proteome, to T2-treatment, a BN-PAGE-based
approach was also used to characterize the profile of the liver
OXPHOS and to measure their individual in-gel activities. In
summary, T2 induced vs. HFD, an enhancement of OXPHOS
activities (complex I, II, and IV) well suggesting reduced oxidative
damage to the respiratory chain itself and a success in efficiently
catabolizing the extra load of fatty acids, likely “sparing” other
metabolically active tissue, specifically the skeletal muscle, coun-
teracting, at the same time, the fat-induced insulin resistance (IR)
attributable to HFD (de Lange et al., 2011). To test this hypoth-
esis, by using the same animal model as in Silvestri et al. (2010),
an integrated approach was designed to assess the effects of T2
on skeletal muscle insulin sensitivity and protein profile (Moreno
et al., 2011). Schematically, without inducing sarcopenia, T2
administration to HFD rats produced in gastrocnemius muscle
an increase in: type II (glycolitic) fibers, glucose transporter 4
(GLUT4) membrane content, glucose utilization (through Akt
activation), and glycolytic enzymes activity, while preventing the
HFD-induced increase in fatty acid uptake (through FAT/CD36)
and intramyocellular lipid (triglyceride) accumulation. The 2-
DE/nano-liquid chromatography-electrospray ionization-linear
ion trap-tandem mass spectrometry (nLC-ESI-LIT-MS/MS)-
based analysis revealed that T2 treatment, while inducing a shift
toward a fast phenotype, significantly altered the gastrocnemius
muscle protein expression profile of HDF rats. In particular,
structural proteins such as the fast isotypes of myosin light
chains (i.e., MLC1f, MLC2f) and the tropomyosin α chain fast
increased significantly following T2 treatment whereas the con-
tent of the slow isotypes MLC1s, MLC2s, and the tropomyosin α
chain slow decreased. Coherently, in T2-treated HFD rats, other
glycolytic enzymes (i.e., α- and β-enolase, and triosophosphate
isomerase) were up-regulated while enzymes involved in oxida-
tivemetabolism (i.e., carbonic anhydrase III andmyoglobin) were
significantly down-regulated vs. HFD control rats (Moreno et al.,
2011).
Overall, these data indicated, for the first time, that T2, at least
at the used dose and in rats, without thyrotoxic effects, can signif-
icantly impact the proteome profile of responsive tissues, such as
liver and skeletal muscle, thus ultimately influencing fuel utiliza-
tion, and energy metabolism in a functional cross-talk between
target organs. In particular, in terms of tissue specific effects of T2,
the liver might be mainly involved in lipid metabolism derange-
ment while the skeletal muscle might be mainly implicated in
glucose utilization.
CONCLUSIONS AND PERSPECTIVES
The biochemical and cellular mechanisms that underlie tissue
specific actions of T3 and T2 are only beginning to be elucidated.
However, the proteomic studies so far conducted separately ana-
lyzed the effects of T3 and T2 in different states of altered energy
balance: changed thyroid state and over-nutrition, respectively
(Figure 1). To further characterize and compare the molecular
and biochemical pathways that underlie T3 and T2 metabolic
actions, T3 and T2 themselves should be used in the same experi-
mental design in comparative approaches so to highlight putative
common effects or iodothyronine-specific one.
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